Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Trial Details

NCT ID
NCT05609578
Phase
PHASE2
Sponsor
Mirati Therapeutics Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adagrasib oral dose of 400 mg twice daily tablets
  • Pembrolizumab
  • Chemotherapy: Pemetrexed
  • Cisplatin/Carboplatin
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Glendale, Arizona, United States|33.53865,-112.18599
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Anaheim, California, United States|33.83529,-117.9145
  • Fountain Valley, California, United States|33.70918,-117.95367

Key Eligibility Criteria

  • Cohort A\* (closed): Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutatio…
  • Cohort C: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squamous only) KRASG12C mutation and histologica…
  • Cohort E: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squamous only) KRASG12C mutation and histologica…
  • Presence of measurable disease per RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →